OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 6.44 EUR -1.53%
Market Cap: 141.3m EUR

EV/EBITDA
Enterprise Value to EBITDA

1.8
Current
-6.1
Median
3.9
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
1.8
=
Enterprise Value
104.4m EUR
/
EBITDA
57.2m EUR
EBITDA Growth EV/EBITDA to Growth
FR
OSE Immunotherapeutics SA
PAR:OSE
Average EV/EBITDA: 53.6
1.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 934.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.1
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.5
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
10.8
6%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
16%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -535.6 N/A N/A
AU
CSL Ltd
ASX:CSL
17.4
12%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.7
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.2 N/A N/A
NL
argenx SE
XBRU:ARGX
327.6
168%
1.9

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
1.8
2-Years Forward
EV/EBITDA
2.5
3-Years Forward
EV/EBITDA
2.4